OTCMKTS:AXIM

AXIM Biotechnologies Stock Forecast, Price & News

$0.65
+0.02 (+3.18 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.63
Now: $0.65
$0.66
50-Day Range
$0.57
MA: $0.68
$0.82
52-Week Range
$0.12
Now: $0.65
$1.44
Volume24,985 shs
Average Volume300,906 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
AXIM Biotechnologies, Inc. is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company's NeuCovix is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. It is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was founded in 2010 and is headquartered in San Diego, California.
AXIM Biotechnologies logo

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AXIM
CUSIPN/A
Phone212-751-0001
Employees4
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Headlines

132 Dolphins Missing In Axim
April 10, 2021 |  msn.com
Over 80 mammals washed ashore in Axim
April 5, 2021 |  msn.com
AXIM Biotechnologies Inc Stock , AXIM
December 25, 2020 |  markets.businessinsider.com
News for AXIM Biotechnologies Inc
December 24, 2020 |  markets.businessinsider.com
Axim Biotechnologies Inc
December 17, 2020 |  bloomberg.com
AXIM Biotechnologies Inc Stock
December 5, 2020 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

0.42 out of 5 stars

Medical Sector

1720th out of 2,010 stocks

Biotechnology Industry

101st out of 143 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.65
+0.02 (+3.18 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXIM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXIM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AXIM Biotechnologies (OTCMKTS:AXIM) Frequently Asked Questions

What stocks does MarketBeat like better than AXIM Biotechnologies?

Wall Street analysts have given AXIM Biotechnologies a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AXIM Biotechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AXIM Biotechnologies?

AXIM Biotechnologies saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 700 shares, a decline of 86.8% from the February 28th total of 5,300 shares. Based on an average daily trading volume, of 349,600 shares, the short-interest ratio is presently 0.0 days.
View AXIM Biotechnologies' Short Interest
.

How has AXIM Biotechnologies' stock price been impacted by COVID-19 (Coronavirus)?

AXIM Biotechnologies' stock was trading at $0.1781 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AXIM stock has increased by 264.9% and is now trading at $0.6499.
View which stocks have been most impacted by COVID-19
.

Who are AXIM Biotechnologies' key executives?

AXIM Biotechnologies' management team includes the following people:
  • Mr. John W. Huemoeller II, Pres, CEO & Director (Age 66, Pay $210k)
  • Mr. Robert T. Malasek, CFO & Sec. (Age 53, Pay $30k)
  • Dr. Sergei A. Svarovsky Ph.D., Chief Scientific Officer & Co-Founder of Sapphire Biotech
  • Dr. Douglas Lake Ph.D., Chief Clinical Officer of Sapphire Biotech
  • Dr. Alim Seit-Nebi Ph.D., CTO & Co-Founder of Sapphire Biotech
  • Ms. Catalina Valencia J.D., Chief Exec. Officer of Sapphire Biotech

Who are some of AXIM Biotechnologies' key competitors?

What other stocks do shareholders of AXIM Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AXIM Biotechnologies investors own include (CGC), Cronos Group (CRON), (APHA), Tilray (TLRY), KushCo (KSHB), Aurora Cannabis (ACB), Curaleaf (CURLF), Charlotte's Web (CWBHF), Fulcrum Therapeutics (FULC) and Alibaba Group (BABA).

What is AXIM Biotechnologies' stock symbol?

AXIM Biotechnologies trades on the OTCMKTS under the ticker symbol "AXIM."

How do I buy shares of AXIM Biotechnologies?

Shares of AXIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AXIM Biotechnologies' stock price today?

One share of AXIM stock can currently be purchased for approximately $0.65.

How many employees does AXIM Biotechnologies have?

AXIM Biotechnologies employs 4 workers across the globe.

What is AXIM Biotechnologies' official website?

The official website for AXIM Biotechnologies is aximbiotech.com.

How can I contact AXIM Biotechnologies?

The company can be reached via phone at 212-751-0001.


This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.